Physician

Jill Marie Bilek, MD

According to 2025 Medicare claims, Jill Bilek, MD (NPI: 1497243331) practices infectious disease in the Panama City-Panama City Beach, FL market, with the plurality of this provider's patient population coming from Bay, FL. This provider's primary affiliated billing organization is EMERALD COAST INFECTIOUS DISEASES MEDICAL GROUP, P.A. (NPI: 1720017882; TIN: 562483799) and primary practice location at 32541-0137.

Bilek's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 246 traditional Medicare patients, billed 586,245 HCPCS/CPT codes, and received $984,264 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 507 prescription claims across 114 beneficiaries totaling $157,070 in drug costs, led by Nuzyra (Omadacycline Tosylate). Open Payments data shows 27 records totaling $1,034. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $651 to $157,070. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$492K$984K2023 Medicare payment: $43,695 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $984,264 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022N/RN/RN/R
20233173,653$43,695
2024246586,245$984,264

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$79K$157K2018 Drug cost: $651 (USD; Tot_Drug_Cst)2019 Drug cost: $8,519 (USD; Tot_Drug_Cst)2020 Drug cost: $9,284 (USD; Tot_Drug_Cst)2021 Drug cost: $53,050 (USD; Tot_Drug_Cst)2022 Drug cost: $116,773 (USD; Tot_Drug_Cst)2023 Drug cost: $140,090 (USD; Tot_Drug_Cst)2024 Drug cost: $157,070 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/R15$651
201937124$8,519
202051158$9,284
202128210$53,050
202226137$116,773
202324101$140,090
2024114507$157,070

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99204New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more129129$125
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more144439$98
96365Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less1172,008$47
J2406Injection, oritavancin (kimyrsa), 10 mg519,120$32
96367Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less44531$21

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
NuzyraOmadacycline Tosylate1477$35,007
DaptomycinDaptomycin23135$8,296
ErtapenemErtapenem Sodium1390$5,077
MeropenemMeropenem18111$3,743
CefadroxilCefadroxil26948$3,079

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.27$1,034Amgen Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Jill Marie Bilek, MD?

Tedicare shows public-source Medicare data for Jill Marie Bilek, MD (NPI 1497243331), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jill Marie Bilek, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jill Marie Bilek, MD?

Jill Marie Bilek, MD is linked to EMERALD COAST INFECTIOUS DISEASES MEDICAL GROUP, P.A. (billing NPI 1720017882) in the available physician profile data.

Does Jill Marie Bilek, MD have Open Payments data?

Jill Marie Bilek, MD has 27 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.